SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
-----------------------------
Date of report (Date of earliest event reported) March 13, 2003
------------------------------
INSPIRE PHARMACEUTICALS, INC.
--------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-31135 04-3209022
- -------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
4222 Emperor Boulevard, Suite 470, Durham, North Carolina 27703-8466
- -------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (919) 941-9777
---------------------------
- ------------------------------------------------------------------------------
(Former Name or Former Address, If Changed Since Last Report)
Item 5. Other Events.
On March 13, 2003, Inspire Pharmaceuticals, Inc. (the "Company")
entered into an underwriting agreement (the "Underwriting Agreement") with
Deutsche Bank Securities and U.S. Bancorp Piper Jaffray Inc. with respect to
the issuance and sale by the Company of up to 5,750,000 shares (the "Shares") of
the Company's common stock, $0.001 par value. The Shares will be issued pursuant
to a Registration Statement on Form S-3 (File No. 333-102595) filed with the
Securities and Exchange Commission under the Securities Act of 1933, as amended.
The Underwriting Agreement is filed as Exhibit 1.1 hereto.
Item 7. Financial Statements and Exhibits.
(C) Exhibits.
Exhibit No. Description of Exhibit
----------- ----------------------
1.1 Underwriting Agreement by and between the
Company and Deutsche Bank Securities and
U.S. Bancorp Piper Jaffray Inc. dated
March 13, 2003
* * * * *
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Inspire Pharmaceuticals, Inc.
By: /s/ Gregory J. Mossinghoff
------------------------------------
Gregory J. Mossinghoff
President, Treasurer and
Secretary
Dated: March 14, 2003